Editas Medicine Announces First Quarter 2016 Results and Update

Editas Medicine Announces First Quarter 2016 Results and Update

May 16, 2016

Advancing pipeline and platform demonstrated by data presented at medical and scientific conferences as well as achievement of Juno Therapeutics milestone

Strengthened effort to develop medicines for cystic fibrosis through agreement with Cystic Fibrosis Foundation Therapeutics .

Robust foundation of intellectual, financial, and human capital positions Editas for long-term success

Editas Medicine Announces Agreement with Cystic Fibrosis Foundation Therapeutics to Advance New CRISPR/Cas9 Medicines

Editas Medicine Announces Agreement with Cystic Fibrosis Foundation Therapeutics to Advance New CRISPR/Cas9 Medicines

May 16, 2016

Editas to Receive up to $5 Million Award to Fund Genome Editing Research

Evelo Biosciences Participates in White House Office of Science and Technology Policy’s National Microbiome Initiative Event

Evelo Biosciences Participates in White House Office of Science and Technology Policy’s National Microbiome Initiative Event

May 13, 2016

CAMBRIDGE, Mass., May 13, 2016/PRNewswire/-- Evelo Biosciences, the pioneer of Oncobiotic™ Therapies, microbiome-based therapeutics for cancer, is dedicating $1M to award up to 10 grants for joint studies exploring the human microbiome and cancer. Evelo will participate in the National Microbiome Initiative Event, hosted by the White House Office of Science and Technology Policy on Friday, May 13th.

Editas Medicine Announces Closing of Initial Public Offering and Full Exercise of Option to Purchase Additional Shares

Editas Medicine Announces Closing of Initial Public Offering and Full Exercise of Option to Purchase Additional Shares

February 8, 2016

CAMBRIDGE, Mass., Feb. 08, 2016 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT) today announced the closing of its initial public offering of 6,785,000 shares of its common stock at a public offering price of $16.00 per share, before underwriting discounts and commissions, including 885,000 additional shares of common stock issued upon the exercise in full by the underwriters of their over-allotment option.

Seres Therapeutics Announces Academic Collaborations to Support Development of Microbiome Therapeutics for Inflammatory Bowel Disease

Seres Therapeutics Announces Academic Collaborations to Support Development of Microbiome Therapeutics for Inflammatory Bowel Disease

May 4, 2016

CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 4, 2016-- Seres Therapeutics, Inc. (NASDAQ: MCRB), a leading microbiome therapeutics platform company, today announced it has entered into two separate research collaborations with leading academic groups to support Seres’ ongoing development of the first potential microbiome therapeutics for inflammatory bowel disease (IBD).

Editas Medicine Achieves Milestone under its Collaboration with Juno Therapeutics

Editas Medicine Achieves Milestone under its Collaboration with Juno Therapeutics

May 4, 2016

CAMBRIDGE, Mass., May 04, 2016 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, announced today that it has achieved a $2.5 million milestone under its collaboration with Juno Therapeutics, Inc. (NASDAQ:JUNO) for technical progress in a research program to create engineered T cells with chimeric antigen receptors (CAR) and T cell receptors (TCR) to treat cancer. Editas and Juno are pursuing three research programs utilizing Editas’ genome editing technologies, including CRISPR/Cas9, with Juno’s CAR and TCR technologies.

Acceleron Pharma Reports First Quarter 2016 Financial and Operational Results

Acceleron Pharma Reports First Quarter 2016 Financial and Operational Results

May 5, 2016

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery and development of novel therapeutic candidates that engage the body's ability to rebuild and repair its own cells and tissues, today provided a corporate update and reported financial results for the first quarter ended March 31, 2016.

Agios Reports First Quarter 2016 Financial Results

Agios Reports First Quarter 2016 Financial Results

May 5, 2016

CAMBRIDGE, Mass., May 05, 2016 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today reported business highlights and financial results for the first quarter ended March 31, 2016.

Seres Therapeutics Announces Achievement of Target Enrollment of SER-109 Phase 2 Study for the Prevention of Recurrent Clostridium difficile Infection

Seres Therapeutics Announces Achievement of Target Enrollment of SER-109 Phase 2 Study for the Prevention of Recurrent Clostridium difficile Infection

May 2, 2016

Phase 2 data expected in mid-2016 New SER-109

Expanded Access Program initiated at Phase 2 clinical sites

Visterra Appoints Two Industry Leaders to its Board of Directors

Visterra Appoints Two Industry Leaders to its Board of Directors

April 21, 2016

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Visterra, Inc., a clinical-stage biotechnology company, today announced the appointment of Bernadette Connaughton, Head, European Markets, Canada and Australia of Bristol-Myers Squibb, and Steven Holtzman, former Executive Vice President, Corporate Development of Biogen, to the company’s board of directors. Ms. Connaughton and Mr.